Company intelligence / Profile preview

JiaRay Pharmaceuticals, Inc.

Ownership: Private
Development stage: Other

Overview

JiaRay Pharmaceuticals is currently conducting a Phase 1 clinical trial for JR8603 in advanced solid tumors. The trial has two parts: a dose escalation phase to evaluate safety, tolerability, and determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D); and a dose expansion phase to further evaluate safety and preliminary efficacy in specific cohorts[8].

Therapeutic areas: Oncology
Modalities: Chemical drugs
Industry: Biotech

Drug pipeline

1 asset

JR8603

IND

Indications: Cancer

Partnerships

Jiangsu Jiarui Biotechnology Co., Ltd.

Beyond the preview

Go deeper on JiaRay Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JiaRay Pharmaceuticals, Inc..